Treatment of Challenging Mantle Cell Lymphoma Cases

Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology

Stem Cell Transplant Approaches for Patients With Blood Cancers

March 13th 2019

Ruxolitinib Appears to Yields Superior Responses in Polycythemia Vera Subtype

Rituximab Regimen Yields Sustained Survival in Geriatric Mantle Cell Lymphoma

Brexu-cel Demonstrates Real-World Efficacy in R/R B-ALL

June 3rd 2023

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology

Stem Cell Transplant Approaches for Patients With Blood Cancers

March 13th 2019

Ruxolitinib Appears to Yields Superior Responses in Polycythemia Vera Subtype

Rituximab Regimen Yields Sustained Survival in Geriatric Mantle Cell Lymphoma

Brexu-cel Demonstrates Real-World Efficacy in R/R B-ALL

Related Content

$A real-world population of patients with relapsed/refractory B-cell acute lymphoblastic leukemia are reported to have had a high rate of complete remissions following treatment with brexucabtagene autoleucel.$

June 3rd 2023

Oncology Peer Review On-The-Go: Minority Treatment Disparities and Clinical Trial Enrollment

A real-world population of patients with relapsed/refractory B-cell acute lymphoblastic leukemia are reported to have had a high rate of complete remissions following treatment with brexucabtagene autoleucel.

Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology

Podcast

The first episode of CancerNetwork's podcast Oncology Peer Review On-The-Go explores disparities in cancer care treatment among minorities and the significance of a representative sample in clinical trials.

Stem Cell Transplant Approaches for Patients With Blood Cancers

A recently published article highlights the use of CD4-positive/CD8-positive double-positive T cells as a predictive marker for graft-versus-host disease.

March 13th 2019

Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.

Findings from the phase 2 MAJIC-PV trial highlight a superior event-free survival and overall survival following ruxolitinib vs best available treatment in patients with polycythemia vera who were intolerant/resistant to hydroxycarbamide.

Ruxolitinib Appears to Yields Superior Responses in Polycythemia Vera Subtype

Rituximab Regimen Yields Sustained Survival in Geriatric Mantle Cell Lymphoma

Findings from the phase 2 MAJIC-PV trial highlight a superior event-free survival and overall survival following ruxolitinib vs best available treatment in patients with polycythemia vera who were intolerant/resistant to hydroxycarbamide.

Rituximab plus bendamustine and cytarabine continues to show clinical efficacy and favorable outcomes in a population of elderly patients with mantle cell lymphoma.